1. Home
  2. KF vs CDXS Comparison

KF vs CDXS Comparison

Compare KF & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

N/A

Current Price

$66.23

Market Cap

279.4M

Sector

Finance

ML Signal

N/A

Logo Codexis Inc.

CDXS

Codexis Inc.

N/A

Current Price

$1.36

Market Cap

256.3M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
KF
CDXS
Founded
1984
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Major Chemicals
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
279.4M
256.3M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
KF
CDXS
Price
$66.23
$1.36
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.14
AVG Volume (30 Days)
23.4K
★ 636.5K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.82
EPS
★ N/A
N/A
Revenue
N/A
★ $138,590,000.00
Revenue This Year
N/A
$4.97
Revenue Next Year
N/A
$18.69
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 32.30
52 Week Low
$30.99
$0.96
52 Week High
$81.94
$2.98

Technical Indicators

Market Signals
Indicator
KF
CDXS
Relative Strength Index (RSI) 51.68 44.39
Support Level $61.69 $1.38
Resistance Level $68.74 $1.76
Average True Range (ATR) 1.74 0.08
MACD -0.11 0.01
Stochastic Oscillator 58.18 54.35

Price Performance

Historical Comparison
KF
CDXS

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, including equity securities, of Korean companies. Its portfolio consists of companies from different sectors such as auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: